Riddhi Patel, Kevin Joseph Harrington, Myung-Ju Ahn, Lisa F. Licitra, Douglas Adkins, Amaury Daste, Irene BraƱa, Muh-Hwa Yang, Jin You, Kun Xu, Manish Monga, Ye Guo. "A phase 2 study of first-line (1L) domvanalimab (dom), zimberelimab (zim), and chemotherapy (chemo) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Substudy-01 of the VELOCITY-HNSCC platform trial.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.e18011